Lario Therapeutics awarded $6m for Parkinson’s drug research
Biopharmaceutical company Lario Therapeutics has been awarded a $6 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
The grant will be used to fund Lario’s preclinical programme investigating selective CaV2.3 calcium channel inhibition as a novel and disease-modifying approach for treatment of Parkinson’s disease.
There is extensive literature linking calcium channels to pathology of the disease, and it has been demonstrated in preclinical experimental studies that the deletion of CaV2.3 can have a protective effect against Parkinson’s disease progression.
Tom Otis, Professor of Neuroscience UCL and Chief Scientific Officer of Lario Therapeutics, said: “We are grateful to MJFF for their funding support for Lario’s efforts to test and develop a potential new therapy designed to prevent the loss of neurons that causes Parkinson’s disease. If our research is successful, this will represent an important new treatment option for patients.”
Lario is partnering with Professor Richard Wade-Martins and the Oxford Parkinson’s Disease Centre (OPDC) for the study, for the evaluation of Lario compounds in state-of-the-art patient-derived stem cell models of Parkinson’s disease.
Professor Wade-Martins, Professor of Molecular Neuroscience, University of Oxford, and head of the Oxford Parkinson’s Disease Centre, commented: “I am excited to partner with the team at Lario Therapeutics – having grant funding from MJFF is a testament to the impact this study aims to bring to patients. Our research centre works to understand the development of Parkinson’s, with the ultimate aim of targeting the molecular mechanisms of disease, to prevent disease onset or to delay progression. We see great potential in the CaV2.3 programme and are very happy to collaborate to study patient stem cell-derived neuronal models as part of the research.”
Diana Spencer, Senior Digital Content Editor, DDW
